8-K: Cencora Expands Receivables Securitization Facility to $1.5 Billion, Boosting Liquidity

Cencora, Inc. has increased its receivables securitization facility to $1.5 billion and enhanced its accordion feature to $500 million, providing significant additional liquidity and funding for its ongoing business operations.

Summary

• Cencora, Inc. subsidiaries, AmeriSource Receivables Financial Corporation (ARFC) and AmerisourceBergen Drug Corporation (ABDC), entered into the Twenty-Second Amendment to their Amended and Restated Receivables Purchase Agreement on June 30, 2025.
• The amendment increased the size of the receivables securitization facility from $1.45 billion to $1.5 billion.
• The 'Accordion Feature,' which allows for an increase in participating bank commitments, was expanded from $250 million to $500 million.
• The Accordion Feature is now available to the company during any quarter of its fiscal year, providing greater flexibility.
• The facility is designed to provide additional liquidity and funding for the ongoing business needs of Cencora and its subsidiaries.
• Availability under the facility is based on accounts receivables originated by ABDC and ASD Specialty Healthcare, LLC from the sale of pharmaceuticals and other related products and services.
• Cencora, Inc. serves as the performance guarantor for ABDC's and ASD's obligations under the facility.

Sentiment

Score: 7

Explanation: The amendment to the receivables securitization facility provides Cencora with enhanced financial flexibility and increased liquidity, which is a positive development for its ongoing business operations, indicating stable financial management.

Positives

• Increased the receivables securitization facility by $50 million, from $1.45 billion to $1.5 billion, enhancing overall liquidity.
• Expanded the 'Accordion Feature' from $250 million to $500 million, providing greater flexibility to increase commitments from participating banks.
• Made the Accordion Feature available during any quarter of the fiscal year, removing previous temporal restrictions and improving access to additional funding.
• The facility provides crucial liquidity and funding for the ongoing business needs of the company and its subsidiaries.

Negatives

• No explicit negatives are detailed in the document regarding the amendment itself; it primarily focuses on expanding financial flexibility.

Risks

• Failure by the Seller or Servicer to remit collections or pay fees when due, potentially leading to an Amortization Event.
• Any false or misleading representations, warranties, certifications, or statements made by the Seller, Servicer, or Originator.
• A Change of Control occurring with respect to Cencora, Inc. (the Performance Guarantor).
• Default or failure in performance of other covenants by the Seller, Servicer, or any Originator.
• Failure by the Seller to pay any indebtedness when due, or Cencora or its consolidated subsidiaries failing to pay indebtedness exceeding $150,000,000.
• Exceeding financial thresholds, including a three-month average Default Ratio over 1.00%, Dilution Ratio over 5.75%, Delinquency Ratio over 3.50%, or Days Sales Outstanding exceeding 40 days.
• Default or failure by a Collection Bank in performing its duties, or the Seller/Servicer failing to control collection accounts.
• Litigation, investigation, or proceeding that could materially adversely affect the financial position or operations of the Seller or Servicer, or the collectibility of receivables.
• An Event of Bankruptcy occurring with respect to the Seller, Servicer, any Originator, or Cencora.
• The Aggregate Invested Amount exceeding the Purchase Limit.
• The Net Pool Balance falling below the sum of the Aggregate Invested Amount and the Required Reserve.
• ABDC being replaced as Servicer.
• Cencora defaulting on a specific covenant (Section 6.05) of its Credit Agreement.
• ABDC ceasing to own 100% of the Seller's capital stock, or Cencora ceasing to own 100% of each Originator's capital stock.
• ABDC consolidating, merging, or transferring substantially all assets unless ABDC is the survivor.
• Any amendment, modification, or waiver of the Credit Agreement without consent that materially impairs the interests of the Administrator or Purchasers.
• Default or failure by Cencora in performing its Performance Undertaking.
• Termination of the Receivables Sale Agreement or inability of any Originator to transfer receivables to the Seller.
• The Agreement ceasing to be effective, or the Administrator losing its valid and perfected first priority security interest in the Purchased Assets.
• The Internal Revenue Service or PBGC filing a lien on Purchased Assets or assets of the Seller, Cencora, or any affiliate.
• An ERISA Event that could reasonably be expected to result in a material adverse effect on the business, financial condition, operations, or properties of Cencora and its ERISA Affiliates taken as a whole.

Future Outlook

The expanded receivables securitization facility is available to provide additional liquidity and funding for the ongoing business needs of Cencora and its subsidiaries, indicating a proactive approach to ensuring financial stability and operational capacity.

Management Comments

• The amendment to the receivables securitization facility was executed by subsidiaries of Cencora, Inc., with Cencora serving as the performance guarantor, underscoring the company's commitment to maintaining robust liquidity and funding for its operations.

Industry Context

This amendment reflects a common financial strategy for large companies, particularly in the pharmaceutical distribution sector, to optimize working capital and ensure continuous access to liquidity. Receivables securitization facilities are a standard tool for managing cash flow by converting future receivables into immediate funds, which is crucial for high-volume, low-margin industries like pharmaceutical distribution.

Comparison to Industry Standards

• The use of a receivables securitization facility is a common and established practice among large pharmaceutical distributors and other companies with substantial accounts receivable, aligning with global benchmarks for working capital management.
• The facility size of $1.5 billion and the expanded $500 million accordion feature are substantial, indicating Cencora's significant operational scale and its ability to secure favorable financing terms from a consortium of major financial institutions including MUFG Bank, Wells Fargo, PNC Bank, Bank of America, The Toronto-Dominion Bank, and U.S. Bank National Association.
• The detailed Amortization Events and financial covenants outlined in the agreement are typical for such complex financing structures, reflecting standard risk mitigation practices by lenders in the securitization market.

Corporate Governance

Legal Proceedings

• The document outlines that pending litigation, investigation, or proceedings against the Seller or Servicer that could materially impair their ability to perform obligations or affect receivables collectibility could constitute an Amortization Event.
• A final court decision of $150,000,000 or more against Cencora or its consolidated subsidiaries, or $11,625 or more against the Seller, if unpaid and uncontested, would also trigger an Amortization Event.

Related Party Transactions

• The securitization facility involves transactions between Cencora's subsidiaries: AmeriSource Receivables Financial Corporation (Seller), AmerisourceBergen Drug Corporation (Servicer and Originator), and ASD Specialty Healthcare, LLC (Originator).
• ABDC and ASD sell their accounts receivable to ARFC, which then sells interests in these receivables to various purchaser groups.
• Cencora, Inc. acts as the performance guarantor for the obligations of ABDC and ASD under the facility.

Stakeholder Impact

• Shareholders: The increased liquidity and financial flexibility provided by the expanded facility are positive, potentially reducing financial risk and supporting stable operations, which can be viewed favorably.
• Employees: Enhanced financial stability and access to funding contribute to business continuity, indirectly benefiting employees through job security and operational stability.
• Customers and Suppliers: A robust liquidity position ensures the company's ability to meet its financial obligations, fostering trust and stability in its relationships with customers and suppliers.
• Creditors: The amendment clarifies and reinforces the terms of the securitization, providing transparency and security to the lenders involved in the facility.

Next Steps

• Ongoing utilization of the expanded receivables securitization facility to provide liquidity and funding for the company's business needs.
• Continued adherence to the covenants and conditions outlined in the amended agreement, including financial reporting and compliance with various ratios and limits.

Key Dates

Recommendation

Keywords

Cencora, AmerisourceBergen, SEC filing, 8-K, receivables securitization, liquidity, financing, corporate finance, debt facility, capital management, financial flexibility, accounts receivable